Biodegradable implants for sustained drug release in the eye

Pharmaceutical Research

Volumn 27, Issue 10, 2010, Pages 2043-2053

  Lee, Susan S ^a   Hughes, Patrick ^a   Ross, Aron D ^b   Robinson, Michael R ^a  

^a ALLERGAN INC   (United States)

^b Triton Biomedical Inc   (United States)

Author keywords

biodegradable polymer; ocular implant; polylactic acid; polylactic co glycolic acid; sustained release

Indexed keywords

ALGINIC ACID; ARTIFICIAL TEAR; BRIMONIDINE; CHITOSAN; CILIARY NEUROTROPHIC FACTOR; CYCLOSPORIN; DEXAMETHASONE; ETHYLENE VINYL ACETATE COPOLYMER; FLUOCINOLONE ACETONIDE; GANCICLOVIR; GATIFLOXACIN; GELATIN; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; LEVOFLOXACIN; PILOCARPINE; POLYETHYLENE TEREPHTHALATE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYVINYL ALCOHOL; SILICONE; TRIAMCINOLONE ACETONIDE;

BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; BLURRED VISION; CATARACT; CLINICAL TRIAL; CONJUNCTIVITIS; CYTOMEGALOVIRUS RETINITIS; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; DRY EYE; EYE DISCOMFORT; EYE DISEASE; EYE INFLAMMATION; EYE IRRITATION; EYELID EDEMA; GLAUCOMA; GLAUCOMATOUS OPTIC NEUROPATHY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HYPEREMIA; HYPERSENSITIVITY; IMMUNE RESPONSE; INJECTION SITE REACTION; KERATOCONJUNCTIVITIS SICCA; NONHUMAN; OPTIC NERVE DISEASE; PATIENT ATTITUDE; PHOTOPHOBIA; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETINITIS PIGMENTOSA; RETREATMENT; REVIEW; SOFT CONTACT LENS; SUSTAINED DRUG RELEASE; UVEITIS; VITREOUS HEMORRHAGE;

ABSORBABLE IMPLANTS; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EYE DISEASES; HUMANS; POLYMERS;

EID: 77957340876     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0159-x     Document Type: Review

References (66)

1. BR Conway 2008 Recent patents on ocular drug delivery systems Recent Pat Drug Deliv Formul 2 1 1 8 10.2174/187221108783331410 19075892 1:CAS:528:DC%2BD1cXhsVajsb0%3D (Pubitemid 351546429)
2. D Ghate HF Edelhauser 2006 Ocular drug delivery Expert Opin Drug Deliv 3 2 275 87 10.1517/17425247.3.2.275 16506953 1:CAS:528:DC%2BD28XhvVKnsLc%3D (Pubitemid 43338097)
3. VR Kearns RL Williams 2009 Drug delivery systems for the eye Expert Rev Med Devices 6 3 277 90 10.1586/erd.09.4 19419285 1:CAS:528:DC%2BD1MXlsFCnur0%3D
4. ME Myles DM Neumann JM Hill 2005 Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis Adv Drug Deliv Rev 57 14 2063 79 10.1016/j.addr.2005.08.006 16310884 1:CAS:528: DC%2BD2MXht12ksb%2FK (Pubitemid 41740797)
5. T Yasukawa Y Ogura H Kimura E Sakurai Y Tabata 2006 Drug delivery from ocular implants Expert Opin Drug Deliv 3 2 261 73 10.1517/17425247.3.2.261 16506952 1:CAS:528:DC%2BD28XhvVKnsLY%3D (Pubitemid 43338096)
6. M Tanito F Li MH Elliott M Dittmar RE Anderson 2007 Protective effect of TEMPOL derivatives against light-induced retinal damage in rats Invest Ophthalmol Vis Sci 48 4 1900 5 10.1167/iovs.06-1057 17389526 (Pubitemid 351261380)
7. Z Ni P Hui 2009 Emerging pharmacologic therapies for wet age-related macular degeneration Ophthalmologica 223 6 401 10 10.1159/000228926 19622904 1:CAS:528:DC%2BD1MXhtlSjsbfN
8. D Ghate HF Edelhauser 2008 Barriers to glaucoma drug delivery J Glaucoma 17 2 147 56 10.1097/IJG.0b013e31814b990d 18344762 (Pubitemid 351412405)
9. HW Kwak DJ D'Amico 1992 Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection Arch Ophthalmol 110 259 66 1736876 1:CAS:528:DyaK38Xls1Cisr8%3D
10. DF Kiernan WF Mieler 2009 The use of intraocular corticosteroids Expert Opin Pharmacother 10 15 2511 25 10.1517/14656560903160671 19761356 1:CAS:528:DC%2BD1MXhtFCgsrnL
11. RF Spaide LK Chang JM Klancnik, et al. 2009 Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion Am J Ophthalmol 147 298 306 10.1016/j.ajo.2008. 08.016 18929354 1:CAS:528:DC%2BD1MXhtVeisro%3D
12. DJ Pieramici M Rabena AA Castellarin, et al. 2008 Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions Ophthalmology 115 e47 54 10.1016/j.ophtha.2008.06.021 18708258
13. RM Dafer M Schneck TR Friberg WM Jay 2007 Intravitreal ranibizumab and bevacizumab: a review of risk Semin Ophthalmol 22 3 201 4 10.1080/ 08820530701543024 17763246 (Pubitemid 47346972)
14. PJ Rosenfeld RM Rich GA Lalwani 2006 Ranibizumab: phase III clinical trial results Ophthalmol Clin N Am 19 3 361 72
15. RD Jager LP Aiello SC Patel ET Cunningham Jr 2004 Risks of intravitreous injection: a comprehensive review Retina 24 5 676 98 10.1097/00006982-200410000- 00002 15492621 (Pubitemid 39391758)
16. DM Berinstein 2003 New approaches in the management of diabetic macular edema Tech Ophthalmol 1 106 13 10.1097/00145756-200306000-00011
17. S Wadhwa R Paliwal SR Paliwal SP Vyas 2009 Nanocarriers in ocular drug delivery: an update review Curr Pharm Des 15 23 2724 50 10.2174/ 138161209788923886 19689343 1:CAS:528:DC%2BD1MXptVajs78%3D
18. SY Lee SP Chee 2005 Surodex after phacoemulsification J Cataract Refract Surg 31 8 1479 80 10.1016/j.jcrs.2005.08.017 16129266 (Pubitemid 41208019)
19. R Gaudana J Jwala SH Boddu AK Mitra 2009 Recent perspectives in ocular drug delivery Pharm Res 26 5 1197 216 10.1007/s11095-008-9694-0 18758924 1:CAS:528:DC%2BD1MXjvV2ksbw%3D
20. Lee SS, Yuan P, Robinson MR. Ocular implants for drug delivery. In: Wnek GE, Bowlin GL, editors. Encyclopedia of biomaterials and biomedical engineering. New York: Informa Healthcare USA, Inc; 2008. p. 2259-69.
21. JL Davis BC Gilger MR Robinson 2004 Novel approaches to ocular drug delivery Curr Opin Mol Ther 6 2 195 205 15195932 1:CAS:528:DC%2BD2cXntF2ks7s%3D
22. Chu C-C. Biodegradable polymers: an overview. In: Wnek GE, Bowlin GL, editors. Encyclopedia of biomaterials and biomedical engineering. New York: Informa Healthcare USA, Inc; 2008. p. 195-206.
23. H Kimura Y Ogura 2001 Biodegradable polymers for ocular drug delivery Ophthalmologica 215 3 143 55 10.1159/000050849 11340382 1:CAS:528: DC%2BD3MXjvFamu7s%3D (Pubitemid 32525970)
24. Avgoustakis K. Polylactic-co-glycolic acid (PLGA). In: Wnek GE, Bowlin GL, editors. Encyclopedia of biomaterials and biomedical engineering. New York: Informa Healthcare USA, Inc; 2008. p. 2259-69.
25. MS Shive JM Anderson 1997 Biodegradation and biocompatibility of PLA and PLGA microspheres Adv Drug Deliv Rev 28 1 5 24 10.1016/S0169-409X(97)00048-3 10837562 (Pubitemid 27497671)
26. C Landes A Ballon C Roth 2006 Maxillary and mandibular osteosyntheses with PLGA and P(L/DL) LA Implants: a 5-year inpatient biocompatibility and degradation experience Plast Reconstr Surg 117 7 2347 60 10.1097/01.prs. 0000218787.49887.73 16772941 1:CAS:528:DC%2BD2sXlvFKqtQ%3D%3D (Pubitemid 44324279)
27. R Holmes S Cohen G Cornwall K Thomas K Kleinhenz M Beckett 2004 MacroPore resorbable devices in craniofacial surgery Clin Plast Surg 31 393 406 10.1016/j.cps.2004.03.003 15219746 (Pubitemid 38829237)
28. JW Streilein 2003 Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation J Leukocyte Biol 74 179 85 10.1189/jlb.1102574 12885934 1:CAS:528:DC%2BD3sXmt1GgtbY%3D (Pubitemid 38040414)
29. T Moritera Y Ogura Y Honda R Wada SH Hyon Y Ikada 1991 Microspheres of biodegradable polymers as a drug-delivery system in the vitreous Invest Ophthalmol Vis Sci 32 1785 90 2032801 1:STN:280:DyaK3M3js1emug%3D%3D
30. T Moritera Y Ogura N Yoshimura Y Honda R Wada SH Hyon, et al. 1992 Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy Invest Ophthalmol Vis Sci 33 3125 30 1399416 1:STN:280:DyaK3s%2FhsVOhtA%3D%3D
31. GG Giordano P Chevez-Barrios MF Refojo CA Garcia 1995 Biodegradation and tissue reaction to intravitreous biodegradable poly(D, L-lactic-co-glycolic)acid microspheres Curr Eye Res 9 761 8 10.3109/02713689508995797
32. Lacrisert [prescribing information]. Lawrenceville, NJ, USA: Aton Pharma, Inc; 2007. Available at: http://www.lacrisert.com/pdfs/Lacrisert-PI.pdf. Accessed 04/07/2010.
33. D Chang I Garcia J Hunkeler T Minas 1999 Phase II results of an intraocular steroid delivery system for cataract surgery Ophthalmology 106 1172 7 10.1016/S0161-6420(99)90262-2 10366088 1:STN:280:DyaK1M3pt1aisg%3D%3D
34. DT Tan SP Chee L Lim AS Lim 1999 Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation Ophthalmology 106 2 223 31 10.1016/S0161-6420(99)90060-X 9951469 1:STN:280:DyaK1M7js1Khsg%3D%3D
35. DT Tan SP Chee L Lim J Theng M Van Ede 2001 Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye Ophthalmology 108 2172 81 10.1016/S0161-6420(01)00839-9 11733254 1:STN:280:DC%2BD3MnoslCnuw%3D%3D (Pubitemid 33096927)
36. SK Seah R Husain G Gazzard MC Lim ST Hoh FT Oen, et al. 2005 Use of Surodex in phacotrabeculectomy surgery Am J Ophthalmol 139 5 927 8 10.1016/j.ajo.2004.10.052 15860309 1:CAS:528:DC%2BD2MXjslKnsb8%3D (Pubitemid 40614790)
37. JA Haller P Dugel DV Weinberg C Chou SM Whitcup 2009 Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema Retina 29 1 46 51 10.1097/IAE.0b013e318188c814 18827732
38. BD Kuppermann MS Blumenkranz JA Haller GA Williams DV Weinberg C Chou Dexamethasone DDS Phase II Study Group, et al. 2007 Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema Arch Ophthalmol 125 3 309 17 10.1001/archopht.125.3.309 17353400 1:CAS:528:DC%2BD2sXjvVKktLc%3D (Pubitemid 46425557)
39. M Hu G Huang F Karasina VG Wong 2008 Verisome™, a novel injectable, sustained release, biodegradable, intraocular drug delivery system and triamcinolone acetonide Invest Ophthalmol Vis Sci 49 E-Abstract 5627
40. JI Lim MR Wieland A Fung DY Hung V Wong 2009 A phase 1 study evaluating the safety and evidence of efficacy of IBI-20089, a triamcinolone intravitreal injection formulated with the Verisome™ drug delivery technology, in patients with cystoid macular edema Invest Ophthalmol Vis Sci 50 E-Abstract 5395 10.1167/iovs.09-3435
41. X Dong W Shi G Yuan L Xie S Wang P Lin 2006 Intravitreal implantation of the biodegradable cyclosporin a drug delivery system for experimental chronic uveitis Graefes Arch Clin Exp Ophthalmol 244 4 492 7 10.1007/s00417-005-0109-1 16163496 1:CAS:528:DC%2BD28Xjtlymt7o%3D
42. F Kagaya T Usui K Kamiya Y Ishii S Tanaka S Amano, et al. 2002 Intraocular dexamethasone delivery system for corneal transplantation in an animal model Cornea 21 2 200 2 10.1097/00003226-200203000-00015 11862095 (Pubitemid 34188791)
43. W Shi T Liu L Xie S Wang 2005 FK506 in a biodegradable glycolide-co-clatide-co-caprolactone polymer for prolongation of corneal allograft survival Curr Eye Res 30 11 969 76 10.1080/02713680500320752 16282131 1:CAS:528:DC%2BD2MXht1SmtLzN (Pubitemid 43154691)
44. S Einmahl F Behar-Cohen F D'Hermies S Rudaz C Tabatabay G Renard, et al. 2001 A new poly(ortho ester)-based drug delivery system as an adjunct treatment in filtering surgery Invest Ophthalmol Vis Sci 42 3 695 700 11222529 1:STN:280:DC%2BD3M7lt1CjsQ%3D%3D
45. AP Gorle SG Gattani 2009 Design and evaluation of polymeric ocular drug delivery system Chem Pharm Bull (Tokyo) 57 9 914 9 10.1248/cpb.57.914 1:CAS:528:DC%2BD1MXhtlOqtb%2FP
46. R Wada SH Hyon Y Ikada 1992 Injectable microspheres with controlled drug release for glaucoma filtering surgery Invest Ophthalmol Vis Sci 33 3436 41 1428717
47. LR Beck DR Cowsar DH Lewis RJ Cosgrove Jr CT Riddle SR Lowry, et al. 1979 A new long-acting injectable microcapsule system for the administration of progesterone Fertil Steril 31 545 51 446779 1:CAS:528:DyaE1MXks1altbk%3D
48. KG Carrasquillo JA Ricker IK Rigas, et al. 2003 Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres Invest Ophthalmol Vis Sci 44 290 9 10.1167/iovs.01-1156 12506087 (Pubitemid 36134287)
49. I Genta B Conti P Perugini F Pavanetto A Spadaro G Puglisi 1997 Bioadhesive microspheres for ophthalmic administration of acyclovir J Pharm Pharmacol 49 8 737 42 9379347 1:CAS:528:DyaK2sXmt1Wqs7o%3D
50. G Di Colo Y Zambito S Burgalassi A Serafini MF Saettone 2002 Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly(ethylene oxide) Int J Pharm 248 1-2 115 22 10.1016/S0378-5173(02)00421-0 12429465 (Pubitemid 35341415)
51. J-L Bourges SE Gautier F Delie, et al. 2003 Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles Invest Ophthalmol Vis Sci 44 3562 9 10.1167/iovs.02-1068 12882808 (Pubitemid 36909796)
52. Y de Kozak K Andrieux H Villarroya, et al. 2004 Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis Eur J Immunol 34 3702 12 10.1002/eji.200425022 15517615 1:CAS:528:DC%2BD2cXhtFajtrvE (Pubitemid 40012188)
53. C Alvarez-Lorenzo H Hiratani A Concheiro 2006 Contact lenses for drug delivery: achieving sustained release with novel systems Am J Drug Deliv 4 3 131 51 10.2165/00137696-200604030-00002 1:CAS:528:DC%2BD28Xht1ehs73P (Pubitemid 44338313)
54. CL Schultz TR Poling JO Mint 2009 A medical device/drug delivery system for treatment of glaucoma Clin Exp Optom 92 4 343 8 10.1111/j.1444-0938.2009. 00370.x 19389129
55. L Xinming C Yingde AW Lloyd, et al. 2007 Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: a review Cont Lens Anterior Eye 31 2 57 64 10.1016/j.clae.2007.09.002 17962066
56. DA Mohammad BV Sweet SG Elner 2007 Retisert: is the new advance in treatment of uveitis a good one? Ann Pharmacother 41 3 449 54 10.1345/aph.1H540 17341531 1:CAS:528:DC%2BD2sXksVCltLw%3D (Pubitemid 46536036)
57. S Mansoor BD Kuppermann MC Kenney 2009 Intraocular sustained-release delivery systems for triamcinolone acetonide Pharm Res 26 4 770 84 10.1007/s11095-008-9812-z 19184374 1:CAS:528:DC%2BD1MXhtFSlsrw%3D
58. A Arjona S Vasiliou P Cole 2009 Highlights from the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2009 Drugs Future 34 11 925
59. KL Macoul D Pavan-Langston 1975 Pilocarpine Ocusert system for sustained control of ocular hypertension Arch Ophthalmol 93 587 90 1164218 1:STN:280:DyaE28%2Fhsl2ktA%3D%3D
60. HA Quigley IP Pollack TS Harbin Jr 1975 Pilocarpine Ocuserts: long-term clinical trials and selected pharmacodynamics Arch Ophthalmol 93 771 5 1235481 1:STN:280:DyaE2s7ls1KmsQ%3D%3D
61. Chien YW. Novel drug delivery systems. 2nd ed. New York: Marcel Dekker; 1992.
62. SR Kedhar DA Jabs 2007 Cytomegalovirus retinitis in the era of highly active antiretroviral therapy Herpes 14 66 71 18371289
63. FE Kane J Burdan A Cutino KE Green 2008 Iluvien: a new sustained delivery technology for posterior eye disease Expert Opin Drug Deliv 5 9 1039 46 10.1517/17425247.5.9.1039 18754752 1:CAS:528:DC%2BD1cXhtVGktrnK
64. DF Emerich CG Thanos 2008 NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells Curr Opin Mol Ther 10 5 506 15 18830926 1:CAS:528:DC%2BD1cXhtlSgtb3K
65. CG Thanos WJ Bell P O'Rourke K Kauper S Sherman P Stabila, et al. 2004 Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device Tissue Eng 10 11-12 1617 22 10.1089/ten.2004.10.1617 15684670 1:CAS:528:DC%2BD2MXhtVOrt7s%3D
66. Tao W, Wen R, Laties A, Aguirre GD. Cell-based delivery systems: development of encapsulated cell technology for ophthalmic applications. In: Jaffe GJ, Ashton P, editors. Intraocular drug delivery. New York: Taylor & Francis Group; 2006. p. 111-28.